Primary and secondary granule release by polymorphonuclear leukocytes exposed to peritoneal dialysis effluent.
Peritoneal dialysis effluent from patients with end-stage renal failure contains a low-molecular-weight solute that inhibits the killing of phagocytosed Staphylococcus epidermidis by polymorphonuclear leukocytes (PMN). This observation has been investigated by using luciginen-enhanced chemiluminescence to measure PMN NADPH oxidase activity, CD11b/CD18 expression and lactoferrin release to measure secondary granule discharge, and cellular levels of beta-glucuronidase (EC 3.2.1.31) to measure changes in primary granules. Peritoneal dialysis effluent had no effect on the loss of intracellular beta-glucuronidase from normal unstimulated PMN or from PMN stimulated with S. epidermidis. It did, however, cause a concentration-dependent (0 to 70%; vol/vol) increase in expression of CD11b/CD18 and NADPH oxidase activity. CD11b/CD18 expression increased over 20 min before starting to plateau. Release of lactoferrin by the same cells demonstrated a strong positive correlation with integrin expression (P < 0.001, Spearman's rank correlation coefficient). When dialysis effluent-treated PMN were stimulated with formyl-methionylleucylphenylalanine, integrin expression, release of lactoferrin, and NADPH oxidase activity were greater than in PMN treated with formyl-methionylleucylphenylalanine alone. Under these conditions, a concentration-dependent increase in CD11b/ CD18 and lactoferrin release were observed only at a concentration between 0 and 30% (vol/vol) dialysis effluent, while a concentration-dependent increase in oxidase activity was seen at a concentration between 0 and 70% (vol/vol). The results suggest that dialysis effluent does not affect PMN primary granule release but does cause increased release of secondary granules and an increase in NADPH oxidase activity in both unstimulated and stimulated PMN.
D018845:CD11 Antigens / Q000032:analysis; D003594:Cytoplasmic Granules / Q000201:enzymology / Q000276:immunology / Q000378:metabolism*; D015314:Dialysis Solutions / Q000009:adverse effects* / Q000737:chemistry; D005966:Glucuronidase / Q000032:analysis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000201:enzymology / Q000276:immunology* / Q000628:therapy; D008163:Luminescent Measurements; D009247:NADH, NADPH Oxidoreductases / Q000378:metabolism; D019255:NADPH Oxidases; D009504:Neutrophils / Q000201:enzymology / Q000276:immunology* / Q000378:metabolism*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects
D018845:CD11 Antigens; D015314:Dialysis Solutions; D009247:NADH, NADPH Oxidoreductases; D019255:NADPH Oxidases; D005966:Glucuronidase